A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
Phase of Trial: Phase III
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms UNITY 4
- Sponsors Bristol-Myers Squibb
- 07 Jun 2017 Biomarkers information updated
- 31 Mar 2017 Primary endpoint (Proportion of treated subjects with SVR12 in the naive cohort) has been met, according to results published in the Journal of Gastroenterology and Hepatology.
- 31 Mar 2017 Results published in the Journal of Gastroenterology and Hepatology.